Moran Wealth Management LLC Has $23.35 Million Stock Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)

Moran Wealth Management LLC lifted its holdings in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) by 13.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 22,216 shares of the biopharmaceutical company’s stock after purchasing an additional 2,572 shares during the quarter. Moran Wealth Management LLC’s holdings in Regeneron Pharmaceuticals were worth $23,354,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Sachetta LLC boosted its holdings in shares of Regeneron Pharmaceuticals by 71.4% during the 2nd quarter. Sachetta LLC now owns 24 shares of the biopharmaceutical company’s stock worth $26,000 after buying an additional 10 shares during the period. Rakuten Securities Inc. increased its position in shares of Regeneron Pharmaceuticals by 380.0% during the 3rd quarter. Rakuten Securities Inc. now owns 24 shares of the biopharmaceutical company’s stock worth $25,000 after purchasing an additional 19 shares in the last quarter. Stephens Consulting LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 2nd quarter worth about $26,000. Crewe Advisors LLC acquired a new stake in shares of Regeneron Pharmaceuticals during the 1st quarter worth about $28,000. Finally, Lynx Investment Advisory acquired a new stake in Regeneron Pharmaceuticals in the 2nd quarter valued at about $33,000. Institutional investors and hedge funds own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.4 %

Shares of Regeneron Pharmaceuticals stock traded down $3.19 during midday trading on Wednesday, reaching $741.41. 95,411 shares of the company’s stock traded hands, compared to its average volume of 532,731. The company has a debt-to-equity ratio of 0.09, a quick ratio of 4.46 and a current ratio of 5.28. The company has a market cap of $81.47 billion, a PE ratio of 18.43, a price-to-earnings-growth ratio of 2.86 and a beta of 0.15. The stock has a 50 day moving average of $969.72 and a 200-day moving average of $1,032.16. Regeneron Pharmaceuticals, Inc. has a 12 month low of $736.01 and a 12 month high of $1,211.20.

Insiders Place Their Bets

In related news, CFO Christopher R. Fenimore sold 5,680 shares of the stock in a transaction on Wednesday, August 28th. The stock was sold at an average price of $1,205.33, for a total transaction of $6,846,274.40. Following the sale, the chief financial officer now directly owns 15,305 shares of the company’s stock, valued at $18,447,575.65. This trade represents a 27.07 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. 7.48% of the stock is owned by corporate insiders.

Analyst Ratings Changes

Several research analysts have recently issued reports on REGN shares. Leerink Partners reaffirmed a “market perform” rating and issued a $1,077.00 target price (down previously from $1,175.00) on shares of Regeneron Pharmaceuticals in a research note on Tuesday, September 24th. BMO Capital Markets reduced their price objective on shares of Regeneron Pharmaceuticals from $1,300.00 to $1,190.00 and set an “outperform” rating on the stock in a research note on Friday, November 1st. Wells Fargo & Company reduced their price objective on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,050.00 and set an “overweight” rating on the stock in a research note on Tuesday, October 22nd. TD Cowen lifted their price target on shares of Regeneron Pharmaceuticals from $1,030.00 to $1,200.00 and gave the company a “buy” rating in a research note on Tuesday, July 23rd. Finally, Barclays cut their price objective on shares of Regeneron Pharmaceuticals from $1,080.00 to $1,065.00 and set an “overweight” rating on the stock in a research report on Friday, November 1st. One investment analyst has rated the stock with a sell rating, four have given a hold rating, eighteen have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to MarketBeat, the stock currently has an average rating of “Moderate Buy” and an average price target of $1,099.55.

Regeneron Pharmaceuticals Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.